SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Novo Nordisk adds Anthropic's Claude to drug-research workflow

Novo Nordisk (NYSE: NVO) will test Anthropic’s Claude Science on selected scientific questions and deploy it in its drug-research workflow, Reuters reported.

NVONOVOB
SquawkNews Desk

Novo Nordisk NYSE:NVO, the diabetes and obesity pharmaceutical leader, has brought Anthropic's Claude into its drug-research workflow, Reuters reported Wednesday. The U.S. depositary shares traded at $42.125. Novo said it will start by testing Claude Science on selected scientific questions while also deploying…

Related stories

Asian session market picture: S&P 500 +0.56%, Nasdaq 100 +1.24%; USD/JPY +0.11%, WTI +0.66%, 9984 leads volume Asian session market picture. US index futures: S and P futures is up 0.56 percent, Nasdaq futures is up 1.24 percent, Dow futures is up 0.28 percent and Russell futures is up 0.35 M impact | EQUITY | Nov 11, 2026, 03:30 AM UTC Samsung Electronics shares rise 3% M impact | EQUITY | Nov 11, 2026, 03:20 AM UTC Mebuki Financial Raises Annual Dividend Forecast to ¥48 Per Share Mebuki Financial Raises Annual Dividend Forecast to ¥48 Per Share Mebuki Financial Group raised L impact | EQUITY | Nov 11, 2026, 03:09 AM UTC Mebuki Financial Group to Buy Back Up to 0.95% of Shares Mebuki Financial Group plans a share buyback worth up to 10 billion yen. L impact | EQUITY | Nov 11, 2026, 03:02 AM UTC Asian session market picture: S&P 500 +0.44%, Nasdaq 100 +0.96%; USD/JPY +0.06%, WTI +0.56%, 9984 leads volume Asian session market picture. US index futures: S and P futures is up 0.44 percent, Nasdaq futures is up 0.96 percent, Dow futures is up 0.19 percent and Russell futures is up 0.23 M impact | EQUITY | Nov 11, 2026, 03:00 AM UTC Japan’s Nikkei rises for a third day Japan’s Nikkei rose for a third day. The headline attributes the move to data and earnings fueling AI optimism. M impact | EQUITY | Nov 11, 2026, 02:51 AM UTC